Selexis SA has signed a strategic agreement with Zyngenia Inc. in which Selexis will utilize its SURE Cell Line Development Platform to generate production cell lines for Zyngenia’s lead Zybody therapeutic programs. “We are excited to support Zyngenia in the rapid advancement of their lead Zybody products,” said Dr. Igor Fisch, chief executive officer and co-founder of Selexis SA. “It’s rare in today’s biotech environment to find a truly innovative antibody platform such as Zyngenia’s, where ...